These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 26585927

  • 1. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
    Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
    [Abstract] [Full Text] [Related]

  • 2. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 3. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 27; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 5. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN.
    Oncotarget; 2016 Dec 13; 7(50):82943-82952. PubMed ID: 27769042
    [Abstract] [Full Text] [Related]

  • 6. Crizotinib and testing for ALK.
    Shaw AT, Solomon B, Kenudson MM.
    J Natl Compr Canc Netw; 2011 Dec 13; 9(12):1335-41. PubMed ID: 22157554
    [Abstract] [Full Text] [Related]

  • 7. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Dec 13; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 8. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2016 Dec 13; 11(12):2248-2252. PubMed ID: 27613526
    [Abstract] [Full Text] [Related]

  • 9. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    Thorne-Nuzzo T, Williams C, Catallini A, Clements J, Singh S, Amberson J, Dickinson K, Gatalica Z, Ho SN, Loftin I, McElhinny A, Towne P.
    J Thorac Oncol; 2017 May 13; 12(5):804-813. PubMed ID: 28147239
    [Abstract] [Full Text] [Related]

  • 10. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
    Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M.
    Cancer; 2012 Sep 15; 118(18):4486-94. PubMed ID: 22282074
    [Abstract] [Full Text] [Related]

  • 11. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
    Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.
    Oncologist; 2012 Sep 15; 17(11):1351-75. PubMed ID: 22989574
    [Abstract] [Full Text] [Related]

  • 12. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016 Sep 15; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 13. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.
    Arch Pathol Lab Med; 2014 Nov 15; 138(11):1449-58. PubMed ID: 24885803
    [Abstract] [Full Text] [Related]

  • 14. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.
    EBioMedicine; 2016 Jan 15; 3():54-66. PubMed ID: 26870817
    [Abstract] [Full Text] [Related]

  • 15. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
    Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, Chen HJ, Xie Z, Su J, Han JF, Wu YL.
    Clin Lung Cancer; 2016 May 15; 17(3):223-31. PubMed ID: 26454342
    [Abstract] [Full Text] [Related]

  • 16. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 15; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 15; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 18. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
    Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M.
    Cancer; 2013 Nov 15; 119(22):3968-75. PubMed ID: 24022839
    [Abstract] [Full Text] [Related]

  • 19. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 20. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES, Chung JH, Kulig K, Kerr KM.
    Mol Diagn Ther; 2012 Jun 01; 16(3):143-50. PubMed ID: 22506598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.